1. Home
  2. DAWN vs PRGO Comparison

DAWN vs PRGO Comparison

Compare DAWN & PRGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DAWN
  • PRGO
  • Stock Information
  • Founded
  • DAWN 2018
  • PRGO 1887
  • Country
  • DAWN United States
  • PRGO Ireland
  • Employees
  • DAWN N/A
  • PRGO N/A
  • Industry
  • DAWN Biotechnology: Pharmaceutical Preparations
  • PRGO Biotechnology: Pharmaceutical Preparations
  • Sector
  • DAWN Health Care
  • PRGO Health Care
  • Exchange
  • DAWN Nasdaq
  • PRGO Nasdaq
  • Market Cap
  • DAWN 1.3B
  • PRGO 3.9B
  • IPO Year
  • DAWN 2021
  • PRGO 1991
  • Fundamental
  • Price
  • DAWN $12.79
  • PRGO $25.76
  • Analyst Decision
  • DAWN Strong Buy
  • PRGO Buy
  • Analyst Count
  • DAWN 7
  • PRGO 4
  • Target Price
  • DAWN $36.17
  • PRGO $37.00
  • AVG Volume (30 Days)
  • DAWN 937.9K
  • PRGO 1.2M
  • Earning Date
  • DAWN 10-30-2024
  • PRGO 11-06-2024
  • Dividend Yield
  • DAWN N/A
  • PRGO 4.29%
  • EPS Growth
  • DAWN N/A
  • PRGO N/A
  • EPS
  • DAWN N/A
  • PRGO N/A
  • Revenue
  • DAWN $101,953,000.00
  • PRGO $4,392,000,000.00
  • Revenue This Year
  • DAWN N/A
  • PRGO N/A
  • Revenue Next Year
  • DAWN $36.10
  • PRGO $4.51
  • P/E Ratio
  • DAWN N/A
  • PRGO N/A
  • Revenue Growth
  • DAWN N/A
  • PRGO N/A
  • 52 Week Low
  • DAWN $11.94
  • PRGO $23.89
  • 52 Week High
  • DAWN $18.07
  • PRGO $34.60
  • Technical
  • Relative Strength Index (RSI)
  • DAWN 39.97
  • PRGO 36.42
  • Support Level
  • DAWN $12.26
  • PRGO $25.16
  • Resistance Level
  • DAWN $12.81
  • PRGO $28.62
  • Average True Range (ATR)
  • DAWN 0.52
  • PRGO 0.66
  • MACD
  • DAWN -0.05
  • PRGO -0.35
  • Stochastic Oscillator
  • DAWN 28.94
  • PRGO 15.79

About DAWN Day One Biopharmaceuticals Inc.

Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.

About PRGO Perrigo Company plc

Perrigo is one of the largest consumer health companies in the world. Since 2018, Perrigo divested its animal health and generic pharmaceuticals businesses to solely focus on consumer self-care. In North America (two thirds of total sales), the firm's product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. Perrigo also plays in Europe, Australia, and parts of Asia where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.

Share on Social Networks: